SCHEMBL4208245

SCHEMBL4208245

CC(=O)c1ccc(NCCOc2c(-c3ccc(F)cc3)n(C)c3ccccc3c2=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.42
NPSR1 Q6W5P4 2/20 0.41
POLB P06746 3/20 0.41
MAPK1 P28482 1/20 0.41
WDR5 P61964 1/20 0.39
HSD17B10 Q99714 2/20 0.38
CYP2C19 P33261 1/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 2/20 0.38
RXFP1 Q9HBX9 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
USP2 O75604 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
PKM P14618 2/20 0.38
ATM Q13315 1/20 0.37
THRB P10828 1/20 0.37
BLM P54132 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4220932 0.87 HTT (0.46) BRD4NPSR1WDR5HSD17B10CYP2C19
SCHEMBL5048604 0.87 HTT (0.45) BRD4NPSR1WDR5HSD17B10CYP2C19
SCHEMBL5044348 0.84 POLB (0.35) BRD4NPSR1POLBMAPK1WDR5
SCHEMBL4039073 0.84 POLB (0.35) BRD4NPSR1POLBMAPK1WDR5
SCHEMBL14011422 0.83 POLB (0.34) BRD4NPSR1POLBMAPK1WDR5
SCHEMBL5046042 0.82 BRD4 (0.43) BRD4NPSR1WDR5HSD17B10CYP2C19
SCHEMBL4210774 0.80 MAOB (0.47) BRD4NPSR1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL4220227 0.80 BRD4 (0.44) BRD4NPSR1WDR5ATMTHRB
SCHEMBL14011598 0.79 HTT (0.47) NPSR1POLBHSD17B10CYP2C19MAPT
SCHEMBL4216145 0.78 MAOB (0.43) MAPTALDH1A1ATMTHRBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1678157-A4 HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF REDDY US THERAPEUTICS INC (US) 2009-03-18 EP disclosed
US-7456288-B2 Heterocyclic compounds and methods of making and using thereof REDDY US THERAPEUTICS, INC. (US) 2008-11-25 US disclosed
EP-1678157-A2 HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF Reddy US Therapeutics, Inc. (US) 2006-07-12 EP disclosed
US-20050119269-A1 Heterocyclic compounds and methods of making and using thereof DR. REDDY'S LABORATORIES LTD. (IN) 2005-06-02 US disclosed
WO-2005042712-A2 HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF REDDY US THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed
WO-2005040163-A1 HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE) DR. REDDY'S LABORATORIES LTD (IN) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119269-A1 Heterocyclic compounds and methods of making and using thereof PYGM, MYLK, HMOX1 BRD4 784/4885NPSR1 4145/4885POLB 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.